Clinical Trials

Latest Clinical Trials News

Intensive LDL Lowering With a Goal of < 70mg/dl Is Superior to Moderate Lowering for Secondary Prevention of Ischemic Stroke Patients

A randomized parallel-group trial comparing intensive LDL-C lowering to modest lowering for…

Syed Hassan Abbas Kazmi

GALILEO-4D: Rivaroxaban-Aspirin Based Anti-Thrombotic Therapy Post-TAVR Protects From Valve Leaflet Motion Abnormalities

An expanded analysis of 231 patients from the GALILEO trial comparing rivaroxaban-aspirin…

Syed Hassan Abbas Kazmi

ORION-1: 1-Year Follow-Up Data Affirms 2-dose Regimen Using 300 mg of Inclisiran For Persistent LDL-C Lowering

A randomized, double blind, placebo-controlled, phase II clinical trial studying the effect…

Syed Hassan Abbas Kazmi

TWILIGHT Trial: Single Anti-Platelet Therapy (SAPT) Using Ticagrelor Reduces Bleeding Risk And Preserves Ischemia Prevention Post-PCI

A randomized, double-blinded, placebo-controlled trial which enrolled 7119 high risk  patients with…

Syed Hassan Abbas Kazmi

Dual Anti-thrombotic Therapy Safe For Patients with Atrial Fibrillation and Recent PCI:ENTRUST-AF PCI

Results from a phase-IIIb, open-label, multi-center, randomized clinical trial comparing the safety…

Syed Hassan Abbas Kazmi

Fractional Flow Reserve Aids Decision Making for Intermediate Coronary Lesions: 1-Month Data from FORZA Study

Compared with optical coherence tomography (OCT), fractional flow reserve (FFR) was associated…

Mandana Chitsazan, M.D.

IMPROVE-IT Trial: Intensive Lipid-Lowering Cuts CVD Risk in the Elderly

Among patients hospitalized for an acute coronary syndrome (ACS), adding ezetimibe to…

Mandana Chitsazan, M.D.

PROMISE Trial: High-Sensitivity Troponins May Assist in Detecting Obstructive CAD in Symptomatic Outpatients

Increasing concentrations of hsTnI are significantly associated with the presence and severity…

Mandana Chitsazan, M.D.